

 Early Warning System

EBRD-56811

DFF - Orchidia for Pharmaceutical Industries



Quick Facts

Countries	Egypt
Financial Institutions	European Bank for Reconstruction and Development (EBRD)
Status	Approved
Bank Risk Rating	B
Voting Date	2025-10-10
Borrower	Orchidia Pharmaceutical Industries S.A.E.
Sectors	Education and Health, Finance, Industry and Trade
Investment Type(s)	Equity
Investment Amount (USD)	\$ 20.00 million
Project Cost (USD)	\$ 72.90 million



Project Description

According to the Bank's website, the project consists of the provision of an equity investment of USD 20 million to support an acquisition in Orchidia for Pharmaceutical Industries ("Orchidia" or the "Company"), alongside SPE Capital ("SPE") as lead investor, an Africa-focused private equity firm, Proparco, and the Belgian Investment Company for Developing Countries "BIO".

SPE invests through its Private Equity Fund III ("PEF III") Fund (where the Bank is an LP) and leads value creation.

EBRD's participation as a co-investor supports SPE Capital's acquisition of Orchidia and ultimately enables the implementation of the expansion plans, and the improvement of Orchidia's competitiveness and financial performance.



Early Warning System Project Analysis

Categorised B (ESP 2024). Environmental and social risks related to the manufacturing of pharmaceuticals are mainly site-specific and can be managed through the application of good practices during operation.



Investment Description

- European Bank for Reconstruction and Development (EBRD)

An equity investment of USD 20 million.



Private Actors Description

Orchidia Pharmaceutical Industries S.A.E. specializes in ophthalmic pharmaceuticals with a state-of-the-art production facility in Cairo, Egypt. The company maintains a leading position in Egypt's retail ophthalmic drugs market and has built a strong international presence across the Middle East and Africa.



Private Actor 1	Private Actor 1 Role	Private Actor 1 Sector	Relation	Private Actor 2	Private Actor 2 Role	Private Actor 2 Sector
-	-	-	-	Orchidia Pharmaceutical Industries S.A.E.	Client	-



Contact Information

Rehab Gendy
rehab.gendy@orchidiapharmaceutical.com

ACCESS TO INFORMATION

You can request information by emailing: accessinfo@ebrd.com or by using this electronic form:
<https://www.ebrd.com/eform/information-request>

ACCOUNTABILITY MECHANISM OF EBRD

The Project Complaint Mechanism (PCM) is the independent complaint mechanism and fact-finding body for people who have been or are likely to be adversely affected by an European Bank for Reconstruction and Development (EBRD)-financed project. If you submit a complaint to the PCM, it may assess compliance with EBRD's own policies and procedures to prevent harm to the environment or communities or it may assist you in resolving the problem that led to the complaint through a dialogue with those implementing the project. Additionally, the PCM has the authority to recommend a project be suspended in the event that harm is imminent.

You can contact the PCM at: pcm@ebrd.com or you can submit a complaint online using an online form at:
http://www.ebrd.com/eform/pcm/complaint_form?language=en

You can learn more about the PCM and how to file a complaint at: <http://www.ebrd.com/work-with-us/project-finance/project-complaint-mechanism.html>